Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo-controlled, Phase IIa Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) in Patients With Uncomplicated, Gram-positive, Skin Infection

NCT01223222 is registered in ClinicalTrials.gov with Lytix Biopharma AS as lead sponsor.

NCT NCT01223222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01223222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo-controlled, Phase IIa Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) in Patients With Uncomplicated, Gram-positive, Skin Infection
Lead sponsor
Lytix Biopharma AS
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2010
Completion date
February 28, 2011
Enrollment
24 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, gram-positive, skin infections, mild eczema/dermatoses